Scilex Holding Co entered into waivers with Oramed Pharmaceuticals and other investors to avoid defaults on its promissory notes due to a delay in filing its Q3 10-Q report, with a remaining principal of approximately $37 million on the Oramed Note and $41 million on the Tranche B Notes.